A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
Clinical trial NCT06015503 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06015503
- Sponsor
- Avistone Biotechnology Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-21
- Primary completion
- 2025-03-06
- Enrollment
- 139
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.